Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05822245 · ClinicalTrials.gov registry record · Phase 1
A Study of PER-001 in Participants With Open-Angle Glaucoma
A Phase 1 study of Open Angle Glaucoma, sponsored by Perfuse Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05822245: Active Phase 1 study of Open Angle Glaucoma, sponsored by Perfuse Therapeutics.
NCT05822245 is a Phase 1 study of Open Angle Glaucoma that is active but no longer recruiting, run by Perfuse Therapeutics. The registered enrollment target is 36 participants, below the 333-participant average among 28 other Open Angle Glaucoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05822245, a Phase 1 study of Open Angle Glaucoma, is active but no longer recruiting, sponsored by Perfuse Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical study has two phases: Phase 1 and Phase 2a. Phase 1 is an open-label, single ascending dose (SAD), while Phase 2a is a randomized, single-masked (participant) with a sham control.
Primary Outcome
ETDRS or modified ETDRS chart (Charts 1, 2, and R as applicable) with standardized distance and lighting will be used to calculate the LogMAR score
Conditions Studied
Interventions
- DRUG PER-001 Intravitreal Implant - Low Dose
- DRUG PER-001 Intravitreal Implant - High Dose
- DRUG PER-001 Intravitreal Implant - Sham
Study Locations (1)
California
- Perfuse Therapeutics, Inc. - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-05-25 |
| Est. Completion | 2026-04-04 |
| Phase | Phase 1 |
What the registry record for NCT05822245 still lists
NCT05822245 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 333-participant average among 28 other Open Angle Glaucoma trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Open Angle Glaucoma appearing as the primary indexed condition, and to 3 interventions - of which PER-001 Intravitreal Implant - Low Dose is the first listed.
NCT05822245 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05822245 about?
NCT05822245 is a clinical study titled "A Study of PER-001 in Participants With Open-Angle Glaucoma". This clinical study has two phases: Phase 1 and Phase 2a. Phase 1 is an open-label, single ascending dose (SAD), while Phase 2a is a randomized, single-masked (participant) with a sham control.
What is the current status of trial NCT05822245?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2023-05-25. Estimated completion is 2026-04-04.
What conditions does trial NCT05822245 study?
This clinical trial studies the following conditions: Open Angle Glaucoma.
What interventions are being tested in trial NCT05822245?
The interventions under investigation include: PER-001 Intravitreal Implant - Low Dose (DRUG), PER-001 Intravitreal Implant - High Dose (DRUG), PER-001 Intravitreal Implant - Sham (DRUG).
Who is sponsoring clinical trial NCT05822245?
This trial is sponsored by Perfuse Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05822245 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Open Angle Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05822245's enrollment target sits among peer trials
36 23rd of 28 higher than 6 of 28 other Open Angle Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Open Angle Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
RECRUITING · Phase 1
-
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 1
-
Study of ANX007 in Participants With Primary Open-angle Glaucoma
COMPLETED · Phase 1
-
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
RECRUITING · Phase 4
-
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
RECRUITING · NA
-
Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI